{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:14:56Z","timestamp":1778069696755,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.clml.2026.01.018","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:37:46Z","timestamp":1770050266000},"page":"e636-e642.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"given":"Daniel","family":"Ermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Vardell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-247X","authenticated-orcid":false,"given":"Erin","family":"Zacholski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0891-2803","authenticated-orcid":false,"given":"Amanda","family":"Fegley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipenkumar","family":"Modi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalub","family":"Fedak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5731-8226","authenticated-orcid":false,"given":"Suchitra","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haris","family":"Hatic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheeba","family":"Ba Aqeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azra","family":"Borogovac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kira","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalin","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kress","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Travers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Chilakamarri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Brem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabarish","family":"Ayyappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Sigmund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1829","authenticated-orcid":false,"given":"David","family":"Bond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0568-0781","authenticated-orcid":false,"given":"Charlotte","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9848-9497","authenticated-orcid":false,"given":"Boyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6054-5238","authenticated-orcid":false,"given":"Harsh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2026.01.018_bib0001","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for Stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clml.2026.01.018_bib0002","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.01.018_bib0003","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2026.01.018_bib0004","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.01.018_bib0005","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/bloodadvances.2019000984","article-title":"Five-year results of the BEGEV salvage regimen in relapsed\/refractory classical Hodgkin lymphoma","volume":"4","author":"Santoro","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.01.018_bib0006","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2026.01.018_bib0007","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.01.018_bib0008","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"issue":"8852","key":"10.1016\/j.clml.2026.01.018_bib0009","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"9323","key":"10.1016\/j.clml.2026.01.018_bib0010","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clml.2026.01.018_bib0011","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11899-011-0091-0","article-title":"The role of autologous transplantation in Hodgkin lymphoma","volume":"6","author":"von Tresckow","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"issue":"10310","key":"10.1016\/j.clml.2026.01.018_bib0012","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.clml.2026.01.018_bib0013","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.clml.2026.01.018_bib0014","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory hodgkin lymphoma","volume":"126","author":"LaCasce","year":"2015","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.clml.2026.01.018_bib0015","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.01.018_bib0016","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2026.01.018_bib0017","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.01.018_bib0018","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2026.01.018_bib0019","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2026.01.018_bib0020","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.01.018_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"issue":"27","key":"10.1016\/j.clml.2026.01.018_bib0022","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.clml.2026.01.018_bib0023","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.01.018_bib0024","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.01.018_bib0025","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.01.018_bib0026","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.01.018_bib0027","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab + AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:37:15Z","timestamp":1778067435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2152265026000327"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Outcomes With Novel Versus Traditional Chemotherapy Regimens for Relapsed and Refractory Classical Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}